Cabozantinib S-Malate is used for treating advanced renal cell carcinoma, differentiated thyroid cancer, and hepatocellular carcinoma. It was first introduced by Exelixis Inc in its drug Cometriq on Nov 29, 2012. Another drug containing Cabozantinib S-Malate is Cabometyx. 2 different companies have introduced drugs containing Cabozantinib S-Malate.

Cabozantinib S-malate Patents

Given below is the list of patents protecting Cabozantinib S-malate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Cabometyx	US11141413	Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate	Apr 17, 2037	Exelixis Inc
Cabometyx	US9724342	C-met modulator pharmaceutical compositions	Jul 09, 2033	Exelixis Inc
Cabometyx	US11298349	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb 10, 2032	Exelixis Inc
Cometriq	US11298349	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb 10, 2032	Exelixis
Cometriq	US9717720	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb 10, 2032	Exelixis
Cabometyx	US10034873	C-met modulator pharmaceutical compositions	Jul 18, 2031	Exelixis Inc
Cabometyx	US10039757	C-Met modulator pharmaceutical compositions	Jul 18, 2031	Exelixis Inc
Cabometyx	US8877776	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct 08, 2030	Exelixis Inc
Cometriq	US8877776	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct 08, 2030	Exelixis
Cabometyx	US11091439	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan 15, 2030	Exelixis Inc
Cabometyx	US11091440	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan 15, 2030	Exelixis Inc
Cabometyx	US11098015	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan 15, 2030	Exelixis Inc
Cometriq	US11091439	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan 15, 2030	Exelixis
Cometriq	US11091440	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan 15, 2030	Exelixis
Cometriq	US11098015	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan 15, 2030	Exelixis
Cabometyx	US7579473	c-Met modulators and methods of use	Aug 14, 2026	Exelixis Inc
Cometriq	US7579473	c-Met modulators and methods of use	Aug 14, 2026	Exelixis
Cabometyx	US8497284	C-met modulators and method of use	Sep 24, 2024 (Expired)	Exelixis Inc

Add above patents to watchlist

Cabozantinib S-malate's Family Patents

Full family tree